BRITAIN'S Medicines and Healthcare products Regulatory Agency (MHRA) has initiated a pharmacy-level recall of 25 batches of Irbesartan-containing medicines due to contamination with an impurity that could potentially increase the risk of cancer.
Patients are being told to speak to doctors or pharmacists before stopping any treatment, with impacted batches listed at www.gov.uk.
The above article was sent to subscribers in Pharmacy Daily's issue from 16 Aug 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 16 Aug 21
